BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2595 related articles for article (PubMed ID: 28416161)

  • 1. Cellular Senescence: A Translational Perspective.
    Kirkland JL; Tchkonia T
    EBioMedicine; 2017 Jul; 21():21-28. PubMed ID: 28416161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New agents that target senescent cells: the flavone, fisetin, and the BCL-X
    Zhu Y; Doornebal EJ; Pirtskhalava T; Giorgadze N; Wentworth M; Fuhrmann-Stroissnigg H; Niedernhofer LJ; Robbins PD; Tchkonia T; Kirkland JL
    Aging (Albany NY); 2017 Mar; 9(3):955-963. PubMed ID: 28273655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Senolytic drugs: from discovery to translation.
    Kirkland JL; Tchkonia T
    J Intern Med; 2020 Nov; 288(5):518-536. PubMed ID: 32686219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing Senescent Cell Burden in Aging and Disease.
    Pignolo RJ; Passos JF; Khosla S; Tchkonia T; Kirkland JL
    Trends Mol Med; 2020 Jul; 26(7):630-638. PubMed ID: 32589933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease.
    Hickson LJ; Langhi Prata LGP; Bobart SA; Evans TK; Giorgadze N; Hashmi SK; Herrmann SM; Jensen MD; Jia Q; Jordan KL; Kellogg TA; Khosla S; Koerber DM; Lagnado AB; Lawson DK; LeBrasseur NK; Lerman LO; McDonald KM; McKenzie TJ; Passos JF; Pignolo RJ; Pirtskhalava T; Saadiq IM; Schaefer KK; Textor SC; Victorelli SG; Volkman TL; Xue A; Wentworth MA; Wissler Gerdes EO; Zhu Y; Tchkonia T; Kirkland JL
    EBioMedicine; 2019 Sep; 47():446-456. PubMed ID: 31542391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular senescence in bone.
    Farr JN; Khosla S
    Bone; 2019 Apr; 121():121-133. PubMed ID: 30659978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors.
    Zhu Y; Tchkonia T; Fuhrmann-Stroissnigg H; Dai HM; Ling YY; Stout MB; Pirtskhalava T; Giorgadze N; Johnson KO; Giles CB; Wren JD; Niedernhofer LJ; Robbins PD; Kirkland JL
    Aging Cell; 2016 Jun; 15(3):428-35. PubMed ID: 26711051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Clinical Potential of Senolytic Drugs.
    Kirkland JL; Tchkonia T; Zhu Y; Niedernhofer LJ; Robbins PD
    J Am Geriatr Soc; 2017 Oct; 65(10):2297-2301. PubMed ID: 28869295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular senescence in aging and age-related diseases: Implications for neurodegenerative diseases.
    Wissler Gerdes EO; Zhu Y; Weigand BM; Tripathi U; Burns TC; Tchkonia T; Kirkland JL
    Int Rev Neurobiol; 2020; 155():203-234. PubMed ID: 32854855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Senescent cell clearance by the immune system: Emerging therapeutic opportunities.
    Prata LGPL; Ovsyannikova IG; Tchkonia T; Kirkland JL
    Semin Immunol; 2018 Dec; 40():101275. PubMed ID: 31088710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Senescence and the SASP: many therapeutic avenues.
    Birch J; Gil J
    Genes Dev; 2020 Dec; 34(23-24):1565-1576. PubMed ID: 33262144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery, development, and future application of senolytics: theories and predictions.
    Wissler Gerdes EO; Zhu Y; Tchkonia T; Kirkland JL
    FEBS J; 2020 Jun; 287(12):2418-2427. PubMed ID: 32112672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Senescent Cells: Possible Implications for Delaying Skin Aging: A Mini-Review.
    Velarde MC; Demaria M
    Gerontology; 2016; 62(5):513-8. PubMed ID: 27031122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting cellular senescence in metabolic disease.
    Palmer AK; Tchkonia T; Kirkland JL
    Mol Metab; 2022 Dec; 66():101601. PubMed ID: 36116755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigallocatechin gallate suppresses premature senescence of preadipocytes by inhibition of PI3K/Akt/mTOR pathway and induces senescent cell death by regulation of Bax/Bcl-2 pathway.
    Kumar R; Sharma A; Kumari A; Gulati A; Padwad Y; Sharma R
    Biogerontology; 2019 Apr; 20(2):171-189. PubMed ID: 30456590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting cellular senescence with senotherapeutics: senolytics and senomorphics.
    Zhang L; Pitcher LE; Prahalad V; Niedernhofer LJ; Robbins PD
    FEBS J; 2023 Mar; 290(5):1362-1383. PubMed ID: 35015337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Senolytic Drug Fisetin Attenuates Bone Degeneration in the
    Hambright WS; Mu X; Gao X; Guo P; Kawakami Y; Mitchell J; Mullen M; Nelson AL; Bahney C; Nishimura H; Hellwinkel J; Eck A; Huard J
    J Osteoporos; 2023; 2023():5572754. PubMed ID: 36875869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Reduction of Senescent Cell Burden Alleviates Focal Radiotherapy-Related Bone Loss.
    Chandra A; Lagnado AB; Farr JN; Monroe DG; Park S; Hachfeld C; Tchkonia T; Kirkland JL; Khosla S; Passos JF; Pignolo RJ
    J Bone Miner Res; 2020 Jun; 35(6):1119-1131. PubMed ID: 32023351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging senolytic agents derived from natural products.
    Li W; Qin L; Feng R; Hu G; Sun H; He Y; Zhang R
    Mech Ageing Dev; 2019 Jul; 181():1-6. PubMed ID: 31077707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular Senescence: What, Why, and How.
    Regulski MJ
    Wounds; 2017 Jun; 29(6):168-174. PubMed ID: 28682291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 130.